ADVANCED HEALTH INTELLIGENCE LTD (AHI)

The company lodges its notice of cessation of securities.

The company lodges its Quarterly Commentary and Appendix 4C.

The company secured USD$4,000,000 via a convertible note offering to KOR Investments LLC, part of a new facility aiming to raise up to AUD$10,000,000. The company is in negotiations to finalize the Facility's balance.

The company releases its Investor Presentation.

The company releases its notice of cessation of securities.

The entities suspended for over three months failed periodic reports, the oldest outstanding report deadline, and their 2 year deadline for trading plans. If not met, they will be removed from the official list, usually after the first trading day.

The company releases its notice of cessation of securities.

The company has confirmed technical accounting issues and capital constraints as the reasons for the delay in releasing its 2024 Annual Report. The company is working with the auditor to resolve outstanding matters and aims to finalize the audit by early February 2025.

The company is working with its auditor to complete its 2024 financial year Annual Report, expected to be completed by early February 2025, despite delays due to holiday periods.

AHI joins Microsoft ISV success, enabling access to more customers. AHI's Digital Health Check, a webcam or smartphone camera-based digital biomarker health risk assessment, now offered via Microsoft Azure Marketplace. Microsoft has over 10,000 partners globally across the health care sector.

Represents significant IP value increase for AHI. Provides AHI exclusivity to Assessing Multi-Category Disease Risk from User Captured Images according to the claimed systems and methods. AHI has developed unique image processing techniques. Competitive Advantage: Patent protection safeguards AHI's innovative approach.

Unisure and AHI have cemented their collaborative partnership to create new innovative insurance market offerings. AHI has digitised phenotypical digital biomarker data for insurance underwriting risk purposes. Unisure will deploy a digital underwriting and consumer rewards capability using AHI's Digital Health Assessment and Digital Health Check. Soft launch scheduled for December, followed by full market rollout in January 2025.

The company has released updates regarding unquoted securities, the application for quotation of securities, and appendix 2A and 3G.

The company lodges notice of issue, conversion or payment up of unquoted equity securities.

The company lodges application for quotation of securities.

The company announces its AGM results.

The company releases its AGM Presentation.

VITALL has launched AHI's Digital Health Assessment as part of a proactive community health risk mapping project, enabling targeted, cost-effective solutions for underserved communities in remote Canada.

The company's AGM is set for November 29, 2024, but the 2024 Annual Report isn't lodged due to technical accounting issues. The AGM will be adjourned until the report is considered and resolved.

The company releases a letter to accompany Notice of Annual General Meeting.

The company lodges its quarterly Commentary and Appendix 4C.

The Company's Annual General Meeting is scheduled to be held at Steinepreis Paganin, Level 14, QV1, 250 St George's Terrace, Perth WA 6000 on 29 November 2024 at 1:00pm (AWST).

The company has been granted US patent for its innovative technology, "Predicting User Body Volume to Manage Medical Treatment," which enhances healthcare and technology integration.

ASX releases a notice regarding long-term suspended entities. The company's securities have been suspended for more than 3 months. If an entity does not meet the 1 or 2 year deadlines, it will be removed from the official list. The removal will usually take effect from the open of trading on the first trading day after the deadline date.

The company lodges its notice, conversion or payment up of unquoted equity securities.

The company lodges its application for quotation of securities.

The company releases a notice of proposed issue of securities.

The company releases a notice of application for quotation of securities.

AHI has received a AUD$2.5m bridging loan and AUD$1.5m via the settlement of the initial tranche of the placement. AUD$1.25m of the loan will be repaid in cash, plus accrued interest of AUD$125,000 within 6 months, with the remaining AUD$1.25m of the loan to be converted into shares valued at AUD$2.5 million (including the 100% per annum interest rate) (subject to shareholder approval). The Placement that was announced on 15 April 2024 has, subject to shareholder approval, been increased to raise AUD$2,142,500.

AHI is continuing to work with ASX to ensure the satisfaction of all compliance requirements as quickly as possible, and will provide shareholders with a further update regarding developments as the Company works towards the reinstatement of its securities to official quotation on the ASX. The Company expects to have a further update for shareholders following the release of its annual financial accounts which are due for release on or before 30 September 2024.

Shareholders in this company should consider crystallising a capital loss in 2024/25 by selling their shares. This process is now much easier and quicker. It can be achieved online by entering transaction details here. While, this usually makes good economic sense we recommend you seek professional advice before buying or selling securities, your accountant is probably the best person.

The company will present its research findings on the potential return on subscription to a smartphone-based biometric health risk assessment tool at the ISPOR European Conference in November 2024. The study will analyze the budget impact of early identification and intervention for chronic conditions like obesity, heart disease, and type 2 diabetes in the US and Singapore, indicating the potential for significant healthcare cost savings.

The company lodges its preliminary final report.

The Company announces the positive outcome regarding the awarding of a European patent pursuant to Article 97(1) EPC patent application No. 15864375.9 from the European Patent Office for its innovative technology in imaging the human body. Advanced Health Intelligence has successfully expanded our patent coverage for its technology suite, further strengthening its position in the remote digital care space.

Under Listing Rule 17.6, an entity (if not already suspended) that had not paid its annual listing fees by close of business on Wednesday, 21 August 2024 would have its securities suspended from Official Quotation before the commencement of trading on Thursday, 22 August 2024. The Company has failed to pay to ASX the annual listing fees for the year ending 30 June 2025, and each entity's securities are already suspended from quotation.

On 8 November 2023, AHI received a deficiency notification letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(b), which requires it to maintain a minimum of USD $2,500,000 in net shareholders' equity, USD $35,000,000 market value of listed securities, or USD $500,000 net income from continuing operations. On 20 June 2024, the Company presented a compliance plan to a Nasdaq Hearings Panel. Following deliberation, the Panel decided to delist AHI's securities effective 30 July 2024. Notably, this decision only affects AHI's secondary listing on Nasdaq and does not impact its primary listing on the Australian Securities Exchange. Having achieved an unaudited net shareholder equity position exceeding the minimum requirement of USD $2.5 million, AHI is well-positioned to demonstrate its financial compliance. The Company will exercise its right to appeal the Nasdaq decision by 9 August 2024 and is hopeful that having achieved the compliance requirement will be viewed favourably by the Nasdaq panel during their consideration of the appeal. With a strengthened Balance Sheet and reduced operating costs, AHI is confident in its ability to present a compelling case to the Nasdaq Hearing Panel.

The company lodges its Quarterly Commentary & Appendix 4C Q4.

The securities of the company have been suspended for more than three months. If an entity does not meet the 1 or 2 year deadlines, it will be removed from the official list. The removal will usually take effect from the open of trading on the first trading day after the deadline date.

The securities of the company have been suspended for more than three months. If an entity does not meet the 1 or 2 year deadlines, it will be removed from the official list. The removal will usually take effect from the open of trading on the first trading day after the deadline date.

The company releases a notice of application for quotation of securities.

The company releases a notice of application for quotation of securities.

The company releases a notice of application for quotation of securities.

The company releases a notification regarding unquoted securities.

The company releases a notice of application for quotation of securities.

The company releases a notification of cessation of securities.

The Company has received guidelines from the Australian Securities Exchange stating that the Company's securities will be reinstated to trading on the ASX, subject to the satisfaction of certain conditions precedent. These conditions are: The Company securing AUD$4 million in cleared funds in the Company's Bank account, to the satisfaction of the ASX; and AHI will confirm the above in an ASX announcement and release any required ASX forms (including Appendix 3Bs for any proposed security issues).

The company is in discussions with the Australian Securities Exchange regarding funding arrangements announced on April 15, 2024. The company plans to submit a revised funding proposal and confirm the timing of the reinstatement of its securities to trading on the ASX.

The company has received a delisting notification from Nasdaq Stock Market LLC regarding its failure to meet Nasdaq Listing Rule 5550(b), which requires a minimum of US$2,500,000 in net shareholders' equity, $35,000,000 market value of listed securities, or $500,000 net income from continuing operations. The company reported net shareholders' equity of AUD$2,027,882 in its Form 20-F filing with the SEC in the US for the year ended June 30, 2023, leaving a deficiency of USD$1,155,515. AHI has the right to appeal the delisting notification and will provide Nasdaq with its compliance plan and request a further extension to execute it. To address the deficiency, AHI has secured funding initiatives, including a AUD$1.957 million placement with Oakley Capital and seeking shareholder approval for a US shelf offering. The company has also prepared the necessary F-3 registration statement to seek SEC approval for the sale of securities in the US. Nasdaq's written notice does not affect the listing or trading of AHI's ADSs on Nasdaq, and the company will continue evaluating its alternatives to resolve the listing deficiency.

Kalibra launches with AHI's biometrics, enabling precision health monitoring and personalised journeys. Partnership transforms health management with AI-driven biometrics, diagnostics, analytics, and machine learning. Kalibra platform tracks multiple data sources for holistic well-being and personalised actions. Collaboration empowers health professionals with real-time monitoring and data analytics for proactive care.

The company releases its Commentary for the Quarter-Ended March 31, 2024 and Appendix 4C.

The company lodges its Financial Statements Half Year Ended 311223.

The company lodges its Appendix 4D Half-year report.

The company releases a notice of proposed issue of securities.

AHI has commenced a AUD$1.95 million Placement with Oakley Capital as lead manager. AHI has executed a binding terms sheet with Obsidian Global Partners to supply a further AUD$4 million in convertible notes. Up to a further USD$5 million (approx. $AUD7.6 million) is to be raised via the issue of a separate Convertible Note. AHI will seek to obtain an R&D Advance of up to AUD$1.5 million.

AHI has granted an extension to Pharmak Direct's MSA, allowing additional platform integration time. AHI Technology will be embedded in the e-script process, allowing patient screening. Pharmak has a prominent stake in the e-script market throughout the MENA region. First-of-its-kind e-script and mobile screening point-of-sale offering. His Excellency Dr Obaid Al Ketbi continues to support AHI's growth throughout the region.

AHI grants Changlin an extension to conclude exclusive license requirements. AHI executed a binding exclusive, perpetual license with Shanghai-based Changlin Network Technology Ltd on August 2, 2023, subject to certain conditions being met. Changlin is backed by founders with over 50 years of experience in the global health insurance sector. The license agreement includes an upfront payment of USD$10 million to AHI. AHI will receive an annual license fee of USD$5m thereafter. AHI will receive a 25% revenue share of gross sales from Changlin.

There has been a delay in the lodgement of its financial report for the half-year ended 31 December 2023. The delay is to allow the Company's Auditor, PKF Brisbane Audit, time to finalise its review once the Company is able to provide further information on various potential funding solutions which the Company is considering, which is now well progressed. While the Company had anticipated that this would be finalised to allow for the release of the half-year financial report by 29 February 2024, unforeseen circumstances have caused the delay. Trading in the Company's shares is currently suspended by the ASX and will continue to be suspended until the Company can lodge its reviewed half-year financial statements with the ASX. The Company will work closely with PKF Brisbane Audit to finalise the review and expects to be able to lodge by 28 March 2024 but no later than 5 April 2024, and will work with the Auditors to shorten this time frame as far as possible.

The securities of Advanced Health Intelligence Ltd were suspended at AHI's request on 5 February 2024 pending the release of an announcement in relation to various potential funding solutions referred to in its Quarterly Activities Report and Appendix 4C dated 31 January 2024. AHI's securities will now continue to be suspended from quotation under Listing Rule 17.5, due to AHI not having lodged its Half Year Report for the period ended 31 December 2023 by 29 February 2024 as required by Listing Rule 4.2. AHI's securities will remain suspended until such time that ASX is satisfied with AHI's compliance with the Listing Rules, including Listing Rule 3.1 and 4.2 and that it is otherwise appropriate for AHI's securities to be reinstated to quotation.

The Company has been granted an extension to the Nasdaq shareholders' equity deficiency re-compliance period.

The company releases a notice of application for quotation of securities.

The Company is seeking an extension of its voluntary suspension of its securities pending the release of an announcement in relation to various potential funding solutions referred to in the Company's Quarterly Commentary and Appendix 4C, dated 31 January 2024. The Company requests that the voluntary suspension remain in place until the earlier to occur of: the Company's release of the announcement; or the commencement of trading on 7 March 2024.

The company releases a notice of application for quotation of securities.

The Company is seeking an extension to the voluntary suspension of its securities pending the release of an announcement in relation to various potential funding solutions referred to in the Company's Quarterly Commentary and Appendix 4C, dated 31 January 2024. The Company requests that the voluntary suspension remain in place until the earlier to occur of: the Company's release of the announcement; or the commencement of trading on 1 March 2024.

The company releases a replacement Appendix 2A.

The company releases a notice of cancelation of application for quotation of securities.

The Company is seeking an extension to the voluntary suspension of its securities pending the release of an announcement in relation to various potential funding solutions referred to in the Company's Quarterly Commentary and Appendix 4C, dated 31 January 2024. The Company requests that the voluntary suspension remain in place until the earlier to occur of: the Company's release of the announcement referred to in paragraph 1; or the commencement of trading on 23 February 2024.

The company releases a notice of application for quotation of securities.

The Company requests that the voluntary suspension remain in place until the earlier to occur of: the Company's release of the announcement; or the commencement of trading on 16 February 2024.

The securities of Advanced Health Intelligence Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of AHI, pending the release of an announcement regarding various potential funding solutions referred to in AHI's Quarterly Commentary and Appendix 4C dated 31 January 2024.

name changed from Advanced Human Imaging Ltd